| Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa … E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ... PloS one 8 (7), e67946, 2013 | 148 | 2013 |
| Keratin‐18 and micro RNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts P Thulin, G Nordahl, M Gry, G Yimer, E Aklillu, E Makonnen, G Aderaye, ... Liver international 34 (3), 367-378, 2014 | 135 | 2014 |
| Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective … SG Mfinanga, BJ Kirenga, DM Chanda, B Mutayoba, T Mthiyane, G Yimer, ... The Lancet infectious diseases 14 (7), 563-571, 2014 | 133 | 2014 |
| High plasma efavirenz level and CYP2B6* 6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective … G Yimer, W Amogne, A Habtewold, E Makonnen, N Ueda, A Suda, ... The pharmacogenomics journal 12 (6), 499-506, 2012 | 131 | 2012 |
| Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients G Yimer, N Ueda, A Habtewold, W Amogne, A Suda, KD Riedel, ... PLoS One 6 (12), e27810, 2011 | 127 | 2011 |
| Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research H Mohammed, L Oljira, KT Roba, G Yimer, A Fekadu, T Manyazewal Infectious diseases of poverty 9, 1-8, 2020 | 122 | 2020 |
| Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients G Yimer, G Aderaye, W Amogne, E Makonnen, E Aklillu, L Lindquist, ... PloS one 3 (3), e1809, 2008 | 105 | 2008 |
| Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients G Yimer, M Gry, W Amogne, E Makonnen, A Habtewold, Z Petros, ... PloS one 9 (4), e94271, 2014 | 83 | 2014 |
| Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients A Habtewold, W Amogne, E Makonnen, G Yimer, KD Riedel, N Ueda, ... Journal of antimicrobial chemotherapy 66 (10), 2350-2361, 2011 | 72 | 2011 |
| Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients A Habtewold, W Amogne, E Makonnen, G Yimer, H Nylen, KD Riedel, ... The pharmacogenomics journal 13 (6), 484-489, 2013 | 54 | 2013 |
| β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ... The Journal of infectious diseases 206 (7), 1012-1019, 2012 | 52 | 2012 |
| Co-occurrence of Campylobacter Species in Children From Eastern Ethiopia, and Their Association With Environmental Enteric Dysfunction, Diarrhea, and Host … Y Terefe, L Deblais, M Ghanem, YA Helmy, B Mummed, D Chen, N Singh, ... Frontiers in public health 8, 99, 2020 | 49 | 2020 |
| Antimalarial activity of hydromethanolic extract and its solvent fractions of Vernonia amygdalina leaves in mice infected with Plasmodium berghei T Bihonegn, M Giday, G Yimer, A Animut, M Sisay SAGE Open Medicine 7, 2050312119849766, 2019 | 48 | 2019 |
| Burden of tuberculosis and challenges related to screening and diagnosis in Ethiopia H Mohammed, L Oljira, KT Roba, E Ngadaya, T Ajeme, T Haile, A Kidane, ... Journal of clinical tuberculosis and other mycobacterial diseases 19, 100158, 2020 | 45 | 2020 |
| Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts< 200 cells/μL: TB-HAART study, a randomized clinical trial W Amogne, G Aderaye, A Habtewold, G Yimer, E Makonnen, A Worku, ... PLoS One 10 (5), e0122587, 2015 | 44 | 2015 |
| Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity Z Petros, MTM Lee, A Takahashi, Y Zhang, G Yimer, A Habtewold, ... BMC genomics 17, 1-8, 2016 | 42 | 2016 |
| HLA-B* 57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians Z Petros, J Kishikawa, E Makonnen, G Yimer, A Habtewold, E Aklillu Frontiers in pharmacology 8, 245585, 2017 | 41 | 2017 |
| Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury M Mikus, K Drobin, M Gry, J Bachmann, J Lindberg, G Yimer, E Aklillu, ... Liver international 37 (1), 132-140, 2017 | 40 | 2017 |
| CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ... BMC infectious diseases 13, 1-10, 2013 | 36 | 2013 |
| Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study A Habtewold, E Makonnen, W Amogne, G Yimer, G Aderaye, L Bertilsson, ... Pharmacogenomics 16 (10), 1047-1064, 2015 | 32 | 2015 |
